Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2015

View Archived Issues

Tunable BTK inhibitors from Principia Biopharma show promise for autoimmune diseases

Fate Therapeutics establishes collaboration on NK cell-based cancer immunotherapeutics

Enumeral Biomedical updates pipeline progress

Five Prime and Inhibrx sign GITR antibody research collaboration and license agreement

Novogen's Anisina receives FDA orphan drug designation for neuroblastoma

Radius Health's RAD-1901 synergizes with other anticancer agents in breast cancer models

European Commission approves Evotaz for HIV-1 infection in adults

Johnson & Johnson highlights progress of second quarter 2015

Retinal degeneration model devised to test retinal sheet transplants

Protagonist Therapeutics raises funds to advance pipeline of oral peptide drugs

Kallikrein-11 shows potential as a brain tumor biomarker

Immunocore conducts European life sciences' largest private financing

Achaogen receives NIAID contract to develop novel antibacterials

Avineuro reports results from phase II trial of AVN-211 as schizophrenia adjuvant therapy

Bayer presents GnRH receptor antagonists

FDA grants QIDP designation to iclaprim for hospital-acquired pneumonia

Gilead discloses Na+ channel modulators

Merck & Co patents CETP inhibitors

Esteve divulges multimodal sigma1/mu-opioid receptor ligands

Amgen reports phase II trial results for blinatumomab in Ph+ ALL

Respivert and Topivert disclose protein kinase inhibitors

Yungjin Pharmaceutical starts phase IIa trial of YPL-001 for COPD

Mesenchymal stem cell-derived exosomes can enhance wound healing

New Approaches to Neuroblastoma Therapy consortium starts phase I trial of SF-1126

FDA approves Dysport for upper limb spasticity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...